

Letter to the Editor

Norepinephrine may be an underlying factor in chemobrain

Dear Editor,

Chemotherapy is a widely used and effective treatment for many types of neoplasms, but it is also frequently accompanied by psychological deficits that are referred to as chemotherapy-related cognitive impairment (CRCI), or colloquially as “chemobrain”¹. The pathophysiological processes that underlie CRCI are only beginning to be elucidated. This letter briefly explores the hypothesis that norepinephrine (NE), which is a neurotransmitter in the brain that is also released peripherally by the adrenal glands and sympathetic nervous system, is a prominent factor underlying CRCI. If this hypothesis is correct, it would not only provide basic information on the neurochemical basis of CRCI, but also suggest various neuropharmacological treatments with existing noradrenergic drugs.

While a number of factors besides just chemotherapeutic agents have been suggested to play a role in various cases of CRCI, such as radiation therapy or psychological stress associated with cancer diagnosis, this letter focuses only on the older agents that have been used clinically for decades in many cases. There is evidence that a number of these drugs modulate NE release in the brain and periphery, particularly in animal models. For example, there are data suggesting that vinblastine, vincristine, cyclophosphamide, and doxorubicin can *increase* release of NE in the brain², peripheral organs, and blood plasma^{3,4}, whereas data from other agents suggest *decreases* in NE release or destruction of noradrenergic sympathetic terminals^{5,6}. The possibility that these

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/ijc.33548](https://doi.org/10.1002/ijc.33548)

agents typically increase peripheral NE is reinforced by findings that fatigue and nausea, which frequently accompany chemotherapeutic administration, have been correlated with changes in blood plasma NE.

Since many chemotherapeutic agents do not readily cross the blood-brain barrier, and neither does NE itself, an important question is how intravenously or otherwise peripherally delivered agents could affect brain NE to produce CRCI? One possibility is that since chemotherapy can induce a hyper-inflammatory state that may disrupt the blood-brain barrier, this could allow circulating NE (or various inflammatory molecules) to enter the brain to some degree⁷. It should be noted that chemotherapy has recently been suggested to be accompanied by an inflammatory “cytokine storm”⁸, which itself has been linked with catecholamine signaling such as NE⁹. Another way that peripheral chemotherapy could influence NE in the brain is through the vagus nerve, where this pathway may also be modulated by changes in the intestinal microbiome produced by chemotherapy.

It is indeed plausible that brain NE could play a role in CRCI, since this neurotransmitter is distributed in circuits throughout the brain and is strongly associated with multiple forms of memory (e.g., working, navigational, declarative memory) that can be impaired in CRCI, as well as with depressive symptomatology that may accompany CRCI. Accumulating evidence, both in human subjects and in animal models, suggests that NE has a u-shaped or janus-faced “dose-response” function in various forms of cognition, such that either too much or too little noradrenergic signaling is pathological¹⁰. In this scenario, if some chemotherapeutic agents boost brain NE and others deplete it (perhaps in a subregion-specific manner), then either situation could be pathological and result in CRCI. Alterations of brain NE have also been suggested to play a

role in neurodegenerative disorders such as Alzheimer's and Parkinson's, so it may also be plausible that NE could be a factor underlying neurodegeneration in CRCI.

In summary, older chemotherapeutic agents can in some cases alter peripheral noradrenergic signaling, by either increasing or decreasing it, which may translate into brain alterations of NE either through a disrupted blood-brain barrier or via signaling of the vagus nerve. If brain noradrenergic signaling is increased (perhaps in a long-term manner) by these chemotherapeutic agents, then the widely clinically used and relatively safe noradrenergic transmission-reducing drugs may ameliorate symptoms of CRCI: alpha2 agonists (clonidine, guanfacine, dexmedetomidine), alpha1 antagonists (prazosin, terazosin), beta blockers (propranolol, carvedilol, nebivolol, atenolol). HDAC inhibitors such as valproic acid and vorinostat may also reduce NE transmission and could be effective against CRCI. The latter drugs are also already being used clinically against various types of cancer. On the other hand, if some cases of CRCI are characterized by deficits in noradrenergic signaling, then antidepressants that selectively boost NE may be therapeutic: tricyclics (desipramine, nortriptyline), atomoxetine, reboxetine.

Abbreviations:

(CRCI) chemotherapy-related cognitive impairment

(NE) norepinephrine

Keywords: clonidine; guanfacine; propranolol; prazosin; tricyclic antidepressant

Acknowledgements

Author PJF alone conceived of, wrote, and edited this publication.

Conflict of Interest

The author declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this letter.

Funding

None that directly supported this work.

Paul J. Fitzgerald, Ph.D.

University of Michigan, Department of Psychiatry, Ann Arbor, MI, USA

For correspondence: pafitzge@umich.edu

References

1. Nguyen LD, Ehrlich BE. Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases. *EMBO Mol Med*. April 2020. doi:10.15252/emmm.202012075
2. Sorimachi M. *Changes in Noradrenaline and Its Synthesizing Enzymes in the Nucleus Locus Ceruleus after Intraventricular Administration of Colchicine and Vinblastin*. Vol 59.; 1978.
3. Hanaki Y, Sugiyama S, Akiyama N, Ozawa T. Role of the Autonomic Nervous System in Cyclophosphamide-Induced Heart Mitochondrial Dysfunction in Rats. *Biochem Int*. 1990;21(2):289-295.
4. Langton D, Jover BF, Trigg L, et al. Regional Distribution of the Cardiac Output and Renal Responses to Atrial Natriuretic Peptide Infusion in Rabbits With Congestive Heart Failure. *Clin Exp Pharmacol Physiol*. 1989;16(12):939-951.
5. Bennett T, Gardiner SM, Tomlinson DR. *Selective Noradrenergic Denervation of the Heart Following Intravenous Injections of Vinblastine or Vincristine*. Vol 293.; 1976.
6. Cheney DL, Hanin I, Massarelli R, Trabucchi M, Costa E. VINBLASTINE AND VINCRIStINE: A STUDY OF THEIR ACTION ON TISSUE CONCENTRATIONS OF EPINEPHRINE, NOREPINEPHRINE AND ACETYLCHOLINE*. *Neuropharmacology*. 1973;12(3):233-238.
7. Wardill HR, Mander KA, Van Sebille YZA, et al. Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. *Int J Cancer*. 2016;139(12):2635-2645. doi:10.1002/ijc.30252
8. Filippou P, Karagiannis G. Cytokine storm during chemotherapy: a new companion diagnostic emerges? *Oncotarget*. 2020;11(3):213-215.
9. Konig MF, Powell MA, Staedtke V, et al. Preventing cytokine storm syndrome in COVID-19 using α -1 adrenergic receptor antagonists. *J Clin Invest*. April 2020. doi:10.1172/JCI139642
10. Arnsten AFT. Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: A rational bridge between genetics and the symptoms of mental illness. *Cereb Cortex*. 2007. doi:10.1093/cercor/bhm033